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a  b  s  t  r  a  c  t
Dengue  is  one  of  the  most  important  and  wide-spread  viral  infections  affecting  human  populations.  The
last  few  decades  have  seen  a dramatic  increase  in  the global  burden  of dengue,  with  the  virus  now  being
endemic  or near-endemic  in over 100  countries  world-wide.  A  recombinant  tetravalent  vaccine  candidate
(CYD-TDV)  has  recently  completed  Phase  III clinical  efﬁcacy  trials  in South  East  Asia and  Latin  America
and  has  been  licensed  for use  in  several  countries.  The  trial results  showed  moderate-to-high  efﬁcacies
in  protection  against  clinical  symptoms  and hospitalisation  but  with  so  far  unknown  effects  on  transmis-
sion  and  infections  per  se.  Model-based  predictions  about  the  vaccine’s  short-  or long-term  impact  on  the
burden of  dengue  are  therefore  subject  to a  considerable  degree  of  uncertainty.  Furthermore,  different
immune  interactions  between  dengue’s  serotypes  have  frequently  been  evoked  by modelling  studies  to
underlie  dengue’s  oscillatory  dynamics  in  disease  incidence  and serotype  prevalence.  Here  we  show  how
model assumptions  regarding  immune  interactions  in  the form of antibody-dependent  enhancement,
temporary  cross-immunity  and  the  number  of infections  required  to  develop  full  immunity  can  signif-
icantly  affect  the  predicted  outcome  of a dengue  vaccination  campaign.  Our  results  thus  re-emphasise
the  important  gap  in our  current  knowledge  concerning  the  effects  of previous  exposure  on  subsequent
dengue  infections  and  further  suggest  that  intervention  impact  studies  should  be critically  evaluated  by
their underlying  assumptions  about  serotype  immune-interactions.
©  2016  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license. Introduction
Dengue is a vector-borne viral illness of increasingly global
mportance (Kyle and Harris, 2008; Simmons et al., 2012). Tra-
itionally associated with the tropics, the geographic expansion
f its two mosquito vectors, Aedes aegypti and Aedes albobictus,
ogether with ongoing globalization and urbanization have resulted
n the invasion and establishment of dengue in much wider latitude
anges (Simmons et al., 2012; Messina et al., 2014; Lourenc¸ o and
ecker, 2014). Treatment of dengue is currently limited to support-
ve care and alleviation of clinical symptoms; and in the absence
f a population-wide vaccination campaign, control efforts against
engue virus (DENV) transmission are currently focused on the
osquito vectors, either through direct measures (e.g. application
f insecticides) or through the limitation of vector breeding habitats
e.g. environmental management) (Simmons et al., 2012).
∗ Corresponding author.
E-mail address: m.recker@exeter.ac.uk (M.  Recker).
ttp://dx.doi.org/10.1016/j.epidem.2016.05.003
755-4365/© 2016 Published by Elsevier B.V. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/4.0/).
The Sanoﬁ Pasteur live attenuated, tetravalent dengue vaccine
(CYD-TDV), Dengvaxia®, the most advanced vaccine candidate to
date, successfully completed Phase III clinical efﬁcacy trials across
several endemic countries in South East Asia and Latin America.
The results showed moderate-to-high efﬁcacy against virolog-
ically conﬁrmed infections, hospitalization and severe dengue
(Sabchareon et al., 2012; Capeding et al., 2014; Hadinegoro et al.,
2015; Villar et al., 2015). However, there were marked variations
between individual serotypes, between naive individuals and indi-
viduals with pre-existing antibodies to dengue serotypes (Dorigatti
et al., 2015; Hadinegoro et al., 2015) and also between countries
with different levels of transmission intensities (Hadinegoro et al.,
2015). Based on available data it is further unclear whether the
vaccine protects equally well against infection and/or onwards
transmission as against clinical symptoms.
Besides these uncertainties regarding vaccine action it is impor-
tant to note that there is currently little consensus regarding the
effect of serotype immune-interactions on infection and trans-
mission probabilities, especially within the context of dengue
modelling (Ferguson and Anderson, 1999; Ferguson et al., 1999;
Cummings et al., 2005; Adams et al., 2006; Wearing and Rohani,
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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006; Nagao and Koelle, 2008; Aguiar et al., 2008; Recker et al.,
009; Wikramaratna et al., 2010; Lourenc¸ o and Recker, 2013, 2010)
also see Andraud et al. (2012) for a systematic review on the most
ommon modelling approaches). For instance, antibody-dependent
nhancement (ADE) and cross-immunity have both been proposed
o underlie dengue’s complex epidemiology and in driving the ubiq-
itous multi-annual periodicities in dengue incidence and serotype
revalence. Contrasting model assumptions further extend to the
otal number of infections that individuals might experience, with
ome models assuming full immunity after a secondary, heterol-
gous exposure whilst others allow consecutive infections by all
our serotypes. Importantly, different assumptions about immunity
nd serotype immune interactions have been shown to gener-
te qualitatively similar epidemiological dynamics (Lourenc¸ o and
ecker, 2013), yet their effect on the impact of vaccination, espe-
ially where the vaccine only offers partial and/or serotype-speciﬁc
rotection, has not yet been explored.
With Dengvaxia® already having been licensed for use in
exico, Brazil, El Salvador and the Philippines, and other vaccine
andidates currently being in the pipeline (Schwartz et al. (2015)),
here has been a growing effort in modelling the population-wide
pplication of a dengue vaccine and its potential impact on dis-
ase burden (Johansson et al. (2011), Chao et al. (2012), Beatty et al.
2012), Coudeville and Garnett (2012), Durham et al. (2013), Ndeffo
bah et al. (2014), Rodriguez-Barraquer et al. (2014), Thavara
t al. (2014)). It is therefore imperative to explore in more detail
he effects of commonly used model assumptions about dengue
erotype immune-interactions on the epidemiological dynamics of
engue following the implementation of a vaccination campaign.
ere, using a spatially explicit, agent-based model, we  demonstrate
ow model assumptions regarding cross-immunity and cross-
nhancement critically affect qualitative and quantitative vaccine
mpact predictions. Our results thus re-emphasize the need for
hese to be carefully evaluated in future impact and cost-beneﬁt
nalyses.
. Results
We  used a spatially explicit, individual-based meta-population
ramework (Lourenc¸ o and Recker, 2013) to simulate and quan-
ify the short- and long-term impact of a dengue vaccination
ampaign under different assumptions about serotype immune-
nteractions (see Section 4). The model was qualitatively ﬁtted
gainst a hyper-endemic setting, with co-circulation of all four
erotypes and seasonal dynamics driven by temporal changes
n mosquito population densities (Supplementary Fig. S1). Pre-
accination epidemiologies were quantiﬁed by averaging over a
0 year period before the start of the intervention campaign. These
ere then compared to the dynamics following the introduction
f a vaccine over a 25-year period. The post-vaccination era was
ivided into relevant periods to analyse and highlight short- and
ong-term impacts separately (e.g. to compare the overall reduction
n incidence over 25 years against the immediate effects within the
rst 10 years). Vaccination impact itself was then determined by the
elationship between pre- and post-vaccination incidence levels
nd age-exposure proﬁles. In this framework we do not explicitly
ifferentiate infection outcomes, such that incidence solely refers
o infection counts and not (symptomatic) disease.
.1. Vaccination impact without serotype immune-interactionsFirst we investigated the impact of routine vaccination with
o immune interactions and four possible consecutive infections,
hich we here refer to as the neutral model.  We  assumed a vaccina-
ion coverage level of 75%, administered as a single dose at the agemics 16 (2016) 40–48 41
of 6 years (see Section 4). Vaccine efﬁcacy levels (in terms of preven-
ting infections) were assumed to be 30% and 70% in dengue-naive
and pre-exposed individuals, respectively, in line with pooled esti-
mates (i.e. aggregated sero-positive and sero-negative estimations)
from the CYD-TDV Phase III trials (Capeding et al., 2014; Villar et al.,
2015; Hadinegoro et al., 2015). For simplicity, however, and in con-
trast to trial data, equal efﬁcacies for all serotypes were assumed.
Under these assumptions we  ﬁnd that both the short- and long-
term effects of vaccination in this hyper-endemic scenario lead to a
moderate reduction in dengue incidence, on average by ≈15–20%,
but with substantial variations between model runs (Fig. 1).
It is likely that the introduction of a dengue vaccine might be
coupled with a population-wide catch-up campaign, in which indi-
viduals within a deﬁned age range are targeted for vaccination
in order to maximise the (short-term) impact on dengue burden.
In our model we realised such a strategy by vaccinating a cer-
tain percentage of the population between the ages of 10 and
50 years, regardless of their prior immune status (see Section 4).
We considered two  catch-up scenarios, one in which the one-off
campaign reached 90% coverage and one limited to 50%; the cov-
erage for routine vaccination was  kept at 75% at 6 years of age
in both cases. As shown in Fig. 2A, the inclusion of a catch-up
campaign has a signiﬁcant and rapid impact on dengue burden,
with incidence brieﬂy dropping to near extinction levels for very
high catch-up rates. Notably, even a 50% catch-up campaign can
potentially reduce dengue incidence by nearly 75% over the ﬁrst
10 years post-vaccination (Fig. 2B). However, and in stark con-
trast to a routine vaccination only programme, dengue incidence
starts to rebound around ﬁve years after the start of vaccination
and might even brieﬂy surpass pre-vaccination levels before sett-
ling down to levels achieved by routine vaccination only (Fig. 2A).
Nevertheless, the overall impact of vaccination over the ﬁrst 25
years when combined with a population-wide catch-up campaign
could be highly beneﬁcial and, importantly, positively correlated
with catch-up efforts.
The particular nature of this vaccine in relation to differential
protection between naive and pre-exposed individuals introduces
a non-linear response in vaccine impact for different age groups.
We addressed this by measuring impact over a wide range of vac-
cination ages and coverages. Fig. 3 illustrates how vaccine impact
changes in response to both the age and coverage of routine vacci-
nation, with and without a 50% catch-up, over two post-vaccination
time periods. In all cases, the weakest impact was found when vac-
cination age was  low, due to the relatively low vaccine efﬁcacy
in dengue-naive individuals. In contrast, vaccine impact could be
maximised when routinely targeting the age group where individ-
uals would, on average, have had experienced their ﬁrst dengue
infection (here between 6 and 12 years of age, best seen in Fig. 3C),
at which point vaccine impact could nearly be doubled under
high coverage levels. This age-range arises from a ﬁne balance
between maximizing the number of individuals who would acquire
high vaccine-induced protection (seropositives) and minimizing
the number of ﬁrst infections. Accordingly, beyond this age range
impact is again reduced, as the beneﬁt of protecting individuals
from ﬁrst infection and boosting seropositives who  could still have
+2 infections would have been lost. These observations imply that
the optimal age group for vaccination will be strongly dependent
on the epidemiological setting, with higher transmission intensities
requiring younger age groups to optimise vaccine impact.
2.2. Vaccination impact with serotype immune-interactionsNext we  considered the effects of serotype immune-interactions
on vaccination impact, where we again considered changes to
dengue incidence and also shifting age patterns as measures of
vaccine impact. Unless stated otherwise we assumed four possible
42 J. Lourenc¸ o, M. Recker / Epidemics 16 (2016) 40–48
Fig. 1. Impact of dengue vaccination without immune-interactions. Results show the outcome of a routine vaccination campaign based on 50 individual model runs, using
a  vaccination coverage of 75% at the age of 6 years (vaccination start at t = 0, vertical dashed lines). Solid lines in timeseries plots are the 1-year averages, with between-run
variability shown as shaded areas. Incidence is presented per 100K individuals. (A) Timeseries showing changes in total, primary and secondary infections (grey, red and
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nfections with no immune-interaction other than the one under
onsideration. As before we assumed a coverage of 75% for routine
accination and 50% for the one-off catch-up targeting a core age
roup of 10–50 years.
.2.1. Maximum number of infections
First we considered the effect of the required number of
nfections for the development of full immunity. Due to the
carcity of clinically apparent tertiary and subsequent infections
Gibbons et al., 2007), many epidemiological models assume full
ross-protection after a secondary, heterologous challenge (see
ohansson et al., 2011; Andraud et al., 2012 for reviews). How-
ver, data from cohort studies have been insufﬁcient to discern
hether the rarity of such events simply reﬂect clinical immu-
ity, whereby third and fourth infections could indeed be common
ig. 2. Impact of dengue vaccination + catch-up without immune-interactions. Results s
uns,  using a vaccination coverage of 75% at age of 6 years and a target age group for catch
ines  in timeseries plots are the 1-year averages, with between-run variability shown as 
he  effect of coupling three possible catch-up campaigns with routine vaccination on tot
0%,  red for routine + catch-up 90%). (B) Boxplots showing the distribution in vaccine im
or  routine + catch-up 50%, red for routine + catch-up 90%), over three different periods p
he  reader is referred to the web  version of the article.)t as the percent reduction in total, primary and secondary incidence (grey, red and
ences to color in this ﬁgure legend, the reader is referred to the web version of the
but clinically silent (Gibbons et al., 2007; Kyle and Harris, 2008;
Endy et al., 2011; Burke et al., 1988; Tien et al., 2010; Lin et al.,
2010; Sharp et al., 2014). A previous study has shown that the
‘twice infected – protected’ hypothesis can have signiﬁcant effects
on vaccine impact (Chao et al., 2012), while another has demon-
strated that relaxing this hypothesis crucially affects estimates of
dengue’s reproductive number (R0) and age-related seroconversion
rates (Wikramaratna et al., 2010). Similarly, in order to ﬁt hyper-
endemic seroprevalence rates we had to adjust the transmission
rates in our model accordingly. This resulted in an increase in R0
from ≈4 in the (neutral) 4-infection model to ≈7 in the 2-infection
model (see Supplementary Fig. 1 and Table 1 for examples and
parameter values).
Despite the increase in R0, the limitation to only two  possible
infections signiﬁcantly lowered total incidence rates (Fig. 4A). The
how the outcome of a routine vaccination campaign based on 50 individual model
-up between 10 and 50 years (vaccination start at t = 0, vertical dashed lines). Solid
shaded areas. Incidence is presented per 100K individuals. (A) Timeseries showing
al dengue incidence (grey for routine vaccination only, blue for routine + catch-up
pact as the percent reduction in incidence (grey for routine vaccination only, blue
ost-vaccination. (For interpretation of the references to color in this ﬁgure legend,
J. Lourenc¸ o, M. Recker / Epidemics 16 (2016) 40–48 43
Fig. 3. Effect of vaccination age and coverage on vaccine impact without immune-interactions. (A) and (B) Vaccination-only impact as the percent reduction in total incidence
relative  to pre-vaccination levels over two time periods post-vaccination (ﬁrst 15 years in A, and ﬁrst 25 years in B). (C) and (D) Impact of vaccination coupled with an initial
catch-up campaign over two post-vaccination time periods (ﬁrst 15 years in C and ﬁrst 25 years in D). In all subplots, there is a clear age-dependence in vaccine impact,
introduced from the unequal vaccine efﬁcacies between naive and seropositive individuals. The catch-up campaign has a strong effect in the short-term impact of the vaccine,
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ge  group for catch-up was  between 10 and 50 years.
redicted vaccine impact was also affected, with incidence start-
ng to rebound almost immediately after the initial catch-up due
o the higher R0, thus greatly reducing the short-term impact on
engue burden (Fig. 4A and B). Furthermore, the effect of vaccina-
ion on the average ages of ﬁrst and second infection were much
ess pronounced in the 2-infection model compared to the neu-
ral model (Fig. 4C and D). These observations demonstrate that
etailed knowledge about the acquisition of clinical and/or ster-
le immunity to dengue over the course of repeated infections is
rucial for model-based vaccine impact predictions.
.2.2. Antibody-dependent enhancement
ADE has been considered in models in various forms, either by
nhancing susceptibility to and/or infectivity of a secondary, het-
rologous infection (Wikramaratna et al., 2010; Cummings et al.,
005; Wearing and Rohani, 2006; Ferguson and Anderson, 1999;
ecker et al., 2009). Here we used both, simply because the explicit
ut probabilistic nature of infection events in our model restricts
he maximum possible level of enhancement compared to dif-
erential equation based models (for example, for a probability
f transmission from human to vector of 0.5 per infectious bite,
DE can only reach a maximum factor of 2). In terms of vac-
ine impact, we found dengue incidence levels rebounding much
uicker after the initial catch-up (Fig. 4E), more than halving the
hort-term impact compared to the neutral model (Fig. 4E and F).y  include a strong rebound effect in incidence (see main text and Fig. 2). The target
Furthermore, although the average ages of ﬁrst and subsequent
infections still increased as a result of vaccination, this was  much
less pronounced in the model assuming ADE (Fig. 4G and H). Hence,
as in the case of complete cross-immunity after secondary infection
(Fig. 4A–D), assumptions regarding immune enhancement after a
primary infection can crucially affect the predictions of vaccination
impact.
2.2.3. Temporary cross-immunity
Finally we investigated whether temporary cross-immunity,
whereby individuals recovering from infection are assumed to be
fully protected against infection by any serotype for a short period
of time and commonly incorporated in dengue models (Wearing
and Rohani, 2006; Nagao and Koelle, 2008; Lourenc¸ o and Recker,
2010; Aguiar et al., 2008; Reich et al., 2013), could affect vaccine
impact predictions. As expected from previous work on our neu-
tral model (Lourenc¸ o and Recker, 2013), we  found that temporary
cross-immunity only has a minimal effect on vaccination impact
(Fig. 4I–L), even when considering a 12 months period of immunity.
This result can be explained by the low probability that individuals
get exposed to a heterotypic serotype within the short window
of protection in our spatially explicit framework (Lourenc¸ o and
Recker, 2013), which is also in line with cohort studies (Gibbons
et al., 2007; Sharp et al., 2014) and a recent mathematical approach
(Reich et al., 2013) that have robustly measured and/or estimated
44 J. Lourenc¸ o, M. Recker / Epidemics 16 (2016) 40–48
Table 1
Parameters and values for the model.
Parameter Description Value [range] Refs.
 maximum number of infections 2 or 4 Johansson et al. (2011), Andraud et al. (2012)
1/ıh intrinsic incubation period 2 days [2–7] Halstead (2007)
1/h human infectious period 4 days [4–12] Vaughn et al. (2000), Gubler et al. (1981)
1/˛h temporary cross-immunity 2–12 months [2–12] Sabin (1952)
h enhancement, second infections 2 [1–5] Reich et al. (2013)
M vectors per human host 0.95–2 [0.3–20] Focks et al. (2000)
av vector biting rate 0.55 per day [0.33–1] Trpis and Hausermann (1986)
1/ıv extrinsic incubation period 7 days [6–12] Watts et al. (1987), Reich et al. (2013)
1/v vector average life-span ≈20 days [8–42] Trpis and Hausermann (1986, 1995), Reich et al. (2013)
v→h vector-to-human transm. prob. per bite [0.33–1] Sabin (1952), Armstrong and Rico-Hesse (2003), Reich et al. (2013)
when  = 2 0.66 –
when  = 4 0.5 –
when  = 4, h = 2 0.475 –
when  = 4, 1/˛h = 12 0.505 –
when  = 4, 1/˛h = 12, h = 2 0.480 –
h→v human-to-vector transm. prob. equal to v→h Sabin (1952), Armstrong and Rico-Hesse (2003)
 introduction rate (rand. serotype) 0.03 per day –
Nh human host population size 3.6 million –
ω  daily mobility 0.000001 per day –
ah , bh Weibull scale, shape (humans) 0.0002, 10 –
av, bv Weibull scale, shape (mosquito) 0.007, 6 –
L  number of communities (L × L lattice) 100 –
H  number of humans cummunities 360 –
1/h human average life-span 60 years –
R0 dengue’s reproduction number Johansson et al. (2011)
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when  = 4 ≈4.2 
he time between infections to be several times above the often
odelled range. Note, previous work has shown that even periods
f 24 months of cross-protection do not alter the epidemiological
ynamics of dengue within this spatially-explicit setting (Lourenc¸ o
nd Recker, 2013), such that the expected effect on vaccination
mpact would be equally small.
.2.4. Comparison of serotype immune-interactions
Fig. 5 summarises the comparison between the contrasting
esults of the neutral, 2-infections, ADE and temporary cross-
mmunity models. We  also consider temporary cross-immunity in
ombination with ADE, but found the effect to be only marginal and
ith differences compared to the neutral model mostly driven by
he effects of immune enhancement. It is important to note, how-
ver, that model discrepancies in terms of impact predictions are
ost pronounced in the short-term, i.e. within the ﬁrst 10 years
ost-vaccination. Furthermore, all models agree with an overall
ositive effect over the 25-year period post-vaccination. The dif-
erences in the resulting age-proﬁles of ﬁrst infection, however,
ppear long-lasting, which can have signiﬁcant effects on further
easurements of impact, such as hospitalization rates or case
everity, if these are to be considered as age-dependent.
. Discussion
Immunological serotype interactions are at the heart of many
pidemiological investigations of dengue. The phenomenon of
ntibody-dependent enhancement in particular has received much
ttention and can be considered as one of the major obstacles
n vaccine development, as it suggests that neutralizing antibod-
es must be raised to protective levels against all four serotypes
imultaneously (Messer et al., 2014; Flipse and Smit, 2015). It also
eatures prominently in the published modelling literature where
nhancement of and/or susceptibility to secondary infections are
roposed as possible drivers of dengue’s multi-annual patterns in
ncidence and serotype prevalences. Temporary cross-protection
n individuals recovering from a recent infection has also been put
orward as one of the desynchronising forces underlying dengue–
–
epidemiology. Model assumptions further diverge with regards to
cross-immunity in the form of permanent protection against rein-
fection after a secondary heterologous challenge and whether this
clinically apparent protection does have an effect on subsequent
infections and viral transmission or not. In fact, most model dis-
crepancies revolve around the question whether and how previous
exposures to dengue affect the probabilities and transmissibilities
of subsequent infections (Andraud et al., 2012; Johansson et al.,
2011).
We  have previously shown that within an individual-based
meta-population framework, the explicit incorporation of immune
competition between serotypes is not necessary to reproduce
dengue’s ubiquitous epidemiological patterns (Lourenc¸ o and
Recker, 2013). The unique ﬂexibility of this framework therefore
allowed us to examine how model-based predictions of dengue
vaccination impact could be affected by underlying assumptions
about serotype immune interactions. We  focused particularly on
intervention-mediated shifts in incidence and age-exposure pro-
ﬁles, as these may  be used to deﬁne important metrics for the
evaluation of health-economic beneﬁts and risks associated with
the introduction of a dengue vaccine.
Analysis of the neutral model without immune-interactions
within a hyper-endemic transmission setting showed that the rel-
atively low efﬁcacy of CYD-TDV, particularly in naive individuals,
would only result in a modest but stable ≈15–20% reduction in
dengue incidence (compared to pre-vaccination levels) when using
routine vaccination only at the age of 6. When vaccination was
introduced around the mean age of ﬁrst infection, this could poten-
tially increase to ≈35%. When coupled with a nation-wide catch-up
campaign to maximise short-term impact our results conﬁrmed
the expected and rapid reduction in incidence, which, dependent
on catch-up coverage and vaccine target age, could brieﬂy go
near extinction levels. In the long-term, however, we observed a
rebound in dengue incidence, driven by the incomplete vaccine-
induced protection and demographic turnover in the population,
that might potentially surpass pre-vaccination levels. While this
undesired effect was shown to be temporary, with total long-
term impacts generally being positive regardless of this rebound,
J. Lourenc¸ o, M. Recker / Epidemics 16 (2016) 40–48 45
Fig. 4. Effect of immune-interactions on vaccination impact. Comparison of pre- and post-vaccination dynamic behaviour and vaccine impact between the neutral model
(grey)  and models with 2 infections (cyan, A–D), antibody-dependent enhancement (ADE, green, E–H) and temporary cross-immunity (CI, orange, I–L). All scenarios include
a  catch-up campaign targeting a core group of individuals between 10 and 50 years of age with coverage 50%; routine vaccination coverage was  75% of individuals at 6
years  of age. Incidence is presented per 100K individuals. (First column, A,E,I) Comparative timeseries between neutral and other models, showing the dynamics of total
incidence. Solid lines represent 1-year averages and shaded areas show between-run variability based on 50 individual model runs. (Second column, B,F,J) Quantitative impact
of  vaccination as the percent change in incidence compared to pre-vaccination levels. (Third column, C,G,K) Quantitative impact of vaccination as the percent change in the
age  of ﬁrst infection compared to pre-vaccination levels. (Fourth column, D,H,L) Quantitative impact of vaccination as the percent change in the age of secondary infection
compared to pre-vaccination levels. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
Fig. 5. Comparison of impact predictions between immune-interactions. Boxplots summarising and comparing impact predictions of vaccination + catch-up between the
neutral model (grey) and models assuming 4 types of serotype immune-interactions: full immunity after 2 infections (cyan), antibody-dependent enhancement (ADE, green),
temporary cross-immunity (CI, orange) and ADE + CI (magenta). Impact predictions are based on the relative reductions in total incidence (A) and increases in average ages
of  primary (B) and secondary (C) infections for three relevant post-vaccination time periods. The catch-up campaign targets a core group of individuals between 10 and 50
years  of age with coverage 50%; routine vaccination coverage was  75% of individuals at 6 years of age. Results are based on 50 independent simulations. (For interpretation
of  the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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here is clearly an important trade-off between maximising short-
erm impact and guarding against long-term repercussions, which
e-emphasizes the growing awareness and support for the imple-
entation of other control measures alongside vaccination as part
f an integrated intervention programme (Johansson et al., 2011).
We further considered the effects of the three most widely
sed assumptions about dengue serotype immune-interactions
Andraud et al., 2012) on vaccination impact and found that two  of
hese had a pronounced effect: ADE and the maximum number of
onsecutive dengue infections that an individual might experience
efore developing complete immunity. Although both assumptions
eature frequently in the modelling literature it should be noted
hat these present extreme ends of a spectrum. That is, although the
ccurrence of third and fourth dengue infections is not contested, it
s often argued that these do not contribute signiﬁcantly to dengue
ransmission. Equally, while the susceptibility/infectivity enhance-
ent of secondary infections is due to the observed increase in risk
f severe infection outcomes in these infections, it is clear that not
very secondary infection is enhanced. Therefore, our results con-
erning these two types of immune interactions should equally be
een as extreme points, with more realistic assumptions probably
eading to somewhat less pronounced effects.
The inclusion of temporary cross-immunity did not notice-
bly change the post-vaccination epidemiology of dengue, with
ncidence rates and average ages of infection following the start
f vaccination being comparable to those predicted by the neu-
ral model without cross-immunity. This is not too surprising,
owever, as we have previously shown that temporary cross-
mmunity, at least within this spatially explicit setting, does not
ause any appreciable changes in simulated epidemiologies, sim-
ly because only a small proportion of the population would ever
xperience a heterologous challenge within the short window of
rotection Lourenc¸ o and Recker (2013). In comparison, ADE and
ull cross-immunity after a secondary infection have a direct effect
n dengue’s force of infection, which in both cases can lead to an
ccelerated rebound following the initial catch-up campaign and
ith it a signiﬁcant decrease in the short-term impact on dengue
ncidence.
An important point to note here is that in the case of assum-
ng full protection after two infections a signiﬁcant parameter
ecalibration was required in our framework (see Table 1). Fitting
his model to match seroprevalence proﬁles from highly endemic
ettings resulted in dengue’s reproductive number to increase to
0 ≈ 7, compared to R0 ≈ 4 in the 4-infection model (both values
re within the wide range of R0 estimates for dengue – see Table S1
f Lourenc¸ o and Recker (2013)). We  argue, however, that the differ-
nces in the qualitative behaviour between the two models are not
imply due to changes in the transmission potential, as demon-
trated in Supplementary Fig. S3. What this implies is that the
nderlying assumptions regarding serotype immune-interactions
an crucially affect parameter values obtained by ﬁtting mathe-
atical models to epidemiological data. Here we demonstrated
hat this in turn can signiﬁcantly affect vaccination impact pre-
ictions, potentially changing the critical vaccination fraction for
isease eradication and control (Johansson et al., 2011).
The difference in vaccine impact under changes to immune
nteractions was particularly pronounced in the average ages of
rst and second infections. Whereas the neutral model showed a
oticeable increase in the ages of infection over all time periods
onsidered, this was markedly reduced when considering either
mmune-enhancement or full protection after two heterologous
nfections. Although not fully explored within this framework, it
s clear that this is an important consideration under the assump-
ion that infection outcomes are partially driven by age as well as
revious exposure. Furthermore, as the CYD-TDV trials showed an
ncrease in hospitalisation rates in young vaccine recipients, theremics 16 (2016) 40–48
is the possibility that vaccine efﬁcacy might also be age- as well
as exposure-dependent, potentially resulting in non-linear feed-
back between maximising population-wide vaccine impact and
minimising the risk for the individual.
In terms of realising vaccination in our model we made a
number of simplifying assumptions. For example, we considered
that vaccination was  administered in a single dose. In reality, as
proposed by CYD-TDV trial data, more doses might be required
for optimal efﬁcacy. In terms of vaccine-induced protection we
were guided by the observations from the recent CYD-TDV vac-
cine trials (Capeding et al., 2014; Villar et al., 2015; Sabchareon
et al., 2012) but crucially assumed that the vaccine was equally
efﬁcacious against all four serotypes, whereas the trials revealed
signiﬁcant heterogeneities (Dorigatti et al., 2015; Hadinegoro
et al., 2015). Although not explored in any detail here, we found
that relaxing this assumption can have a signiﬁcant impact on
long-term serotype dynamics, as viruses for which the vaccine
may  be less efﬁcacious can demonstrate earlier resurgence in the
post-vaccination era (see Supplementary Fig. S4 for examples).
It is also relevant to mention that different modes of vaccine
action have been proposed to explain the trial data, such as lower
immunogenicity in younger children or waning of vaccine-induced
immunity (Wilder-Smith and Massad, 2016). To what degree this
would affect the results presented here will have to be subject
of further research, however. A ﬁnal consideration concerns the
endemic setting in which the vaccine is being introduced. We
restricted our analysis to a hyper-endemic setting for two reasons.
First, the main objective here was to highlight the importance
of serotype immune interactions for model-based predictions
on dengue vaccination impact. Secondly, based on the WHO’s
current recommendation CYD–TDV should not be considered in
settings with low transmission where the vaccine would predom-
inantly administered to sero-negative individuals with potentially
unfavourable outcomes (see e.g. http://www.who.int/wer/2016/
wer9121.pdf?ua=1 and http://www.who.int/immunization/sage/
meetings/2016/april/SAGE April 2016 Meeting Web  summary.
pdf?ua=1&ua=1). Our results suggest similar expectations, as we
predict that vaccination at the youngest age of 9 years, as deﬁned
by CYD-TDV’s licensure, would result in insigniﬁcant vaccine
impact, since the mean age of infection in low transmission areas
would be signiﬁcantly higher.
In summary, here we have demonstrated that commonly
used hypotheses on immunological serotype interactions can sig-
niﬁcantly and differentially affect model-based predictions on
measures of dengue vaccination impact. This highlights once again
the important gap in our current knowledge regarding the devel-
opment of immunity to dengue and its effect on the probability
and transmissibility of subsequent infections. Future model-based
studies should therefore present robust sensitivity analysis sur-
rounding the assumptions on serotype immune-interactions.
4. Methods
4.1. Individual-based model
To investigate the post-vaccination dynamics of dengue we
used a spatially explicit, individual-based meta-population model
as previously formulated and described in Lourenc¸ o and Recker
(2013). Brieﬂy, within this framework, every human and mosquito
host is deﬁned with an unique state representing its epidemi-
ological history. Human individuals are considered to be either
susceptible, exposed, infectious or recovered with respect to each
serotype, allowing up to four sequential infections. Only the sus-
ceptible, exposed and infectious states of the epidemiologically
relevant adult life-stage of the mosquito are considered. The size of
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he human population is kept constant with deaths being replaced
y births. To account for seasonal variation in vector densities, an
nnually driven mosquito birth rate is used. An age-dependent
isk of mortality is assumed for both humans and mosquitoes,
escribed by a continuous Weibull distribution. Mosquitoes have
 per-day biting rate, and unless stated otherwise, equal proba-
ilities in human-to-vector and vector-to-human transmission are
ssumed. All parameter values, ranges found in the literature and
eferences can be found in Table 1. For comparison with the dynam-
cal and extensive sensitivity analysis performed on the original
ramework (Lourenc¸ o and Recker, 2013), most of the parameters
ave been kept the same.
Host population structure is included by subdividing humans
nd mosquitoes into a spatially organised sets of communities,
orming a squared and non-wrapping lattice. Individuals mix
omogeneously within each community. Mosquitoes are further
llowed to disperse locally, implying that each vector can bite
umans belonging to its own and neighbouring communities. Long
istance transmission events, driven by daily human mobility, can
ake place by allowing mosquitoes to bite humans of randomly
hosen, distant patches with low probability.
The model includes demographic, biological and ecological
tochasticities, arising from the probabilistic nature of state
ransitions. For simplicity, we disregard the effects of varying host-
tructure, human mobility or mosquito densities in this study, and
efer the reader to the original publication in which the dynamic
ffects of these demographic factors and other ecological and bio-
ogical parameters are explored in detail Lourenc¸ o and Recker
2013).
.2. Fitting to hyper-endemic setting
To ﬁnd a baseline transmission range for the model that would
e in line with hyper-endemic settings, the age proﬁle of the
uman population with exposure to at least one serotype was
tted against a set of empirical data found in the literature (ref-
rences and examples of model ﬁt can be found in Supplementary
ig. S1). As previously demonstrated Wikramaratna et al. (2010),
onsidering a model assuming full immunity to all four serotypes
fter a secondary infection led to a substantial increase in dengue’s
eproductive number (R0) when ﬁtting to the same data (see
able 1 and Supplementary Fig. S1). This difference was achieved by
hanging the human-to-vector and vector-to-human transmission
robabilities accordingly, therefore keeping the host and vector
emographic dynamics unchanged. The mathematical formulation
f R0 applicable to this framework can be found in Lourenc¸ o and
ecker (2013).
.3. Immunological interactions
For comparison purposes we deﬁned a neutral model (Lourenc¸ o
nd Recker (2013)), in which all immunity related assumptions
ere relaxed – that is, individuals were allowed to experience up
o four heterotypic infections with no immunological interactions
etween the serotypes apart from the exclusion of co-infections. To
ccount for immunological interactions between dengue serotypes,
he following three mechanisms (as well as some combinations)
re considered: (i) temporary cross-immunity (Sabin (1952)),
hereby individuals recovering from infection are fully protected
gainst re-infection for a period of time, (ii) antibody-dependent
nhancement (Simmons et al., 2012; Ferguson and Anderson,
999), which increases both susceptibility to and infectivity of
econdary infections (Recker et al., 2009), and (iii) acquisition of
omplete immunity after two infections only (Wikramaratna et al.
2010)). Since the inclusion of these factors can change the force
f infection in comparison to the neutral model, we  adjusted themics 16 (2016) 40–48 47
human-to-vector and vector-to-human transmission probabilities
accordingly, in order to maintain the same transmission setting
(Table 1).
4.4. Vaccination strategies
We implement vaccination in our model using both catch-up
and routine strategies (alone or in combination). Routine vaccina-
tion is implemented by targeting individuals at the point they reach
a certain age, according to a given coverage probability as a single
dose, with vaccine-induced protection being instantaneous. Pro-
tection is assumed to prevent infections according to given vaccine
efﬁcacy levels, which differ between seropositive and seronegative
individuals (70% and 30%, respectively). Catch-up campaigns, on the
other hand, target a speciﬁc age group regardless of their immune
status (without loss of generality we assumed this to be between
10 and 50 years), with a certain coverage rate and implemented as
a one-off, single pulse event. These assumptions, discussed in the
main text, may  deviate from future campaigns in endemic areas
but are crucial for a simple and robust analysis of the mechanistic
drivers of vaccine outcome between the different model structures
considered in this study. Unless otherwise stated, the target age
for routine vaccination was  6 years assuming a coverage of 75%.
Although not of particular relevance for the purpose of this work,
these values were primarily chosen because (i) 6 marks the start of
school in many countries, which could facilitate vaccine coverage,
and (ii) coverage levels above 80–85% might become economically
and/or logistically infeasible in many dengue endemic settings.
4.5. Measuring vaccination outcomes
To quantify vaccination impact we divided the post-vaccination
era into relevant periods (short-term in 0–10 years, long-term in
0–25 years and mid-term in 15–25 years). In these time ranges,
vaccine impact was  determined by comparing pre- and post-
vaccination incidence levels as well as age-exposure proﬁles. The
pre-vaccination period was  assumed to be the 20 years prior to
vaccine introduction. This was done by measuring averages found
within each time period, across 50 independently simulated popu-
lations. The distributions of vaccine impact predictions is presented
by means of box and whiskers plots, in which the boxes show the
interquartile ranges (lower and upper) and the median, whereas
the lower and upper whiskers show the lowest datum still within
1.5 IQR of the lower quartile and the highest datum still within 1.5
IQR of the upper quartile, respectively.
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